Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00099229
Recruitment Status : Completed
First Posted : December 10, 2004
Last Update Posted : February 23, 2017
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
This purpose of this study is to evaluate the safety and efficacy of Licarbazepine for the treatment of manic episodes of bipolar disorder.

Condition or disease Intervention/treatment Phase
Bipolar Disorder Drug: Licarbazepine Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 320 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Tolerability of Licarbazepine 1000-2000mg/Day in the Treatment of Manic Episodes of Bipolar I Disorder Over 3 Weeks
Study Start Date : November 2004
Actual Primary Completion Date : August 2006
Actual Study Completion Date : August 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bipolar Disorder

Primary Outcome Measures :
  1. Mean reduction in manic episodes and major depressive episodes from baseline to endpoint (Week 3).

Secondary Outcome Measures :
  1. Major improvement in anxiety and depression from baseline to endpoint (Week 3)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of bipolar disorder (type I) with manic or mixed episodes (including patients with/without psychotic features or with/without a history of rapid cycling)
  • In need of psychiatric treatment
  • Cooperation and willingness to complete all aspects of the study

Exclusion Criteria:

  • Current diagnosis other than bipolar I disorder
  • History of schizophrenia or schizoaffective disorder
  • Drug dependence within 1 month prior to study start or testing positive in a urine drug test
  • Suicide attempt within 1 month prior to study start or at immediate risk of harm to self or others
  • Any form of psychotherapy within 1 month prior to study start

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00099229

Layout table for location information
United States, Arkansas
Investigational Site
Little Rock, Arkansas, United States, 72211
United States, California
Investigational Site
Cerritos, California, United States, 90703
Investigational Site
San Diego, California, United States, 92126
United States, Florida
Investigational Site
Port Charlotte, Florida, United States, 33952
United States, Indiana
Investigational Site
Indianapolis, Indiana, United States, 46222
United States, Kansas
Investigational Site
Newton, Kansas, United States, 67114
United States, Nevada
Investigational Site
Las Vegas, Nevada, United States, 89103
United States, North Carolina
Investigational Site
Raleigh, North Carolina, United States, 27609
United States, Ohio
Investigational Site
Cincinnati, Ohio, United States, 45267
United States, Oklahoma
Investigational Site
Oklahoma City, Oklahoma, United States, 73118
United States, Pennsylvania
Investigational Site
Philadelphia, Pennsylvania, United States, 19124
United States, Texas
Investigational Site
Austin, Texas, United States, 78756
Investigational Site
Bellaire, Texas, United States, 77401
Investigational Site
Houston, Texas, United States, 77007
Investigational Site
Houston, Texas, United States, 77021
United States, Washington
Investigational Site
Kirkland, Washington, United States, 98033
Investigational Site
Dijon, France, 21033
Investigational Site
Strasbourg, France, 67091
Russian Federation
Investigational Site
Moscow, Russian Federation, 107076
Investigational Site
Moscow, Russian Federation, 113152
Investigational Site
Moscow, Russian Federation, 123367
Investigational Site
St. Petersburg, Russian Federation, 193019
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Additional Information:
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT00099229    
Other Study ID Numbers: CLIC477D2301
First Posted: December 10, 2004    Key Record Dates
Last Update Posted: February 23, 2017
Last Verified: February 2017
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
bipolar disorder
manic episode
Additional relevant MeSH terms:
Layout table for MeSH terms
Bipolar Disorder
Pathologic Processes
Bipolar and Related Disorders
Mental Disorders